Publications by authors named "David Assis"

Claim this Profile
A
A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: Proof-of-concept application to cholestatic liver disease.
Amit Dahal, Teresa Sierra, Colleen M Hayes, David N Assis, Amin Rostami-Hodjegan

J Pharm Biomed Anal· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis.
Ansgar W Lohse, David N Assis

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical trials in primary sclerosing cholangitis: Making the most of every opportunity?
David N Assis, Johannes R Hov

J Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining Best Practices and Content for Foundational Ambulatory GI and Hepatology Teaching During GI Fellowship.
Amy G Ogurick, Kay Chen, Zain Sobani, David N Assis, Donna Windish

Dig Dis Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive review of systemic sclerosis-primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype.
Areeka Memon, Manvitha Nadella, Morgan Emokpae, David N Assis

Curr Opin Rheumatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors.
Peter D Block, David N Assis

Clin Liver Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of pruritus in primary sclerosing cholangitis: Analysis of the consortium for autoimmune liver disease registry.
Richard Dean, Maryam Yazdanfar, Joseph Zepeda, Cynthia Levy, Craig Lammert, David N Assis

Hepatol Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis.
Pinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, Ignasi Olivas, Ezequiel Mauro, David N Assis

Clin Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sodium hyaluronate microcapsules to promote antitumor selectivity of anacardic acid.
Marlon E P Rosa, Louhana M Rebouças, Samuel P D Marques, Larissa M R Silva, Fernando E T Cunha, David A de Assis

Int J Biol Macromol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microspheres based on galactomannan and Spondias purpurea L. extract to increase antifungal and antibiofilm efficacy against Candida spp.
Tatiana do N P Coutinho, Francisco A M Rodrigues, David A de Assis, Louhana M Rebouças, Thais L Ferreira

Int J Biol Macromol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
autoimmune hepatitis? - Summary of the 5 international autoimmune hepatitis group research workshop 2024.
Bastian Engel, David N Assis, Mamatha Bhat, Jan Clusmann, Joost Ph Drenth

JHEP Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress.
Colleen M Hayes, Gina M Gallucci, James L Boyer, David N Assis, Nisanne S Ghonem

Hepatol Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathophysiology of Cystic Fibrosis Liver Disease.
Vania L Kasper, David N Assis

Pediatr Pulmonol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
Gina M Gallucci, Colleen M Hayes, James L Boyer, Olivier Barbier, David N Assis

Cells· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis.
Nasir Hussain, Christopher Ma, Gideon Hirschfield, Martine Walmsley, Paula Hanford, David Assis

BMJ Open· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.
Zachary M Sellers, David N Assis, Shruti M Paranjape, Meghana Sathe, Frank Bodewes

Hepatology· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
Sonali Kochhar, David N Assis, Cara Mack, Hector S Izurieta, Luigi Muratori

Vaccine· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
African American race does not confer an increased risk of clinical events in patients with primary sclerosing cholangitis.
Maryam Yazdanfar, Joseph Zepeda, Richard Dean, Jialin Wu, Cynthia Levy, David N Assis

Hepatol Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Second-Line Treatment for Primary Biliary Cholangitis.
David N Assis

N Engl J Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing diagnosis and management of liver disease in adults through exome sequencing.
Melanie Zheng, Aaron Hakim, Chigoziri Konkwo, Aimee M Deaton, Lucas D Ward, David N Assis

EBioMedicine· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research gaps and opportunities in autoimmune hepatitis-Results of the international autoimmune hepatitis group research workshop 2022.
Romée J A L M Snijders, David N Assis, Ye H Oo, Marcial Sebode, Richard Taubert

Liver Int· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Management of Primary Sclerosing Cholangitis.
David N Assis, Christopher L Bowlus

Clin Gastroenterol Hepatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Living donor liver transplantation for people with PSC.
Lisa M Forman, Gonzalo Sapisochin, David N Assis, Lionel Arrivé, Annika Bergquist

Hepatology· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease.
Amr Sayed, David N Assis, Marina G Silveira, Yanhong Deng, Maria Ciarleglio

Eur J Gastroenterol Hepatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unique DUOX2ACE2 small cholangiocytes are pathogenic targets for primary biliary cholangitis.
Xi Li, Yan Li, Jintao Xiao, Huiwen Wang, Yan Guo, David N Assis

Nat Commun· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis